There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area.
The existing sensors for physiological measurement are rarely used and may need further validation.
There are no wearable or home-use detection devices on the market capable to measure
substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs).
The devices in development are not intended for diagnostics or treatment.
Most of the devices are intended for laboratory use.
Most of the devices do not have standard software interface through which the devices can transmit the data to the study center.